Ardent Health Partners, Inc.ARDT
About: Ardent Health Partners Inc is an operator of hospitals and a provider of healthcare services in the United States. It provides both general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women's services, neurology, urology, and emergency services, within inpatient and ambulatory care settings. The company has one reportable segment: healthcare services that provides healthcare services predominantly through its ownership and operation of hospitals, certain of which provide related healthcare services through physician practices, outpatient centers, and post-acute facilities. Ardent has 30 acute care hospitals, more than 200 sites of care that operate across six states: Texas, Oklahoma, New Mexico, New Jersey, Idaho, and Kansas.
Employees: 24,900
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
90,271% more call options, than puts
Call options by funds: $6.33M | Put options by funds: $7K
200% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 3 (+2) [Q4]
154% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 13
142% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 12
22% more funds holding
Funds holding: 72 [Q3] → 88 (+16) [Q4]
7.09% more ownership
Funds ownership: 64.94% [Q3] → 72.03% (+7.09%) [Q4]
3% more capital invested
Capital invested by funds: $1.7B [Q3] → $1.76B (+$51.5M) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
RBC Capital Ben Hendrix 36% 1-year accuracy 26 / 73 met price target | 36%upside $21 | Outperform Reiterated | 15 May 2025 |
Guggenheim Jason Cassorla 27% 1-year accuracy 4 / 15 met price target | 17%upside $18 | Buy Maintained | 9 May 2025 |
Mizuho Ann Hynes 25% 1-year accuracy 1 / 4 met price target | 17%upside $18 | Outperform Maintained | 9 Apr 2025 |
Stephens & Co. Scott Fidel 53% 1-year accuracy 19 / 36 met price target | 43%upside $22 | Overweight Reiterated | 1 Apr 2025 |
Stephens & Co. Raj Kumar 86% 1-year accuracy 6 / 7 met price target | 43%upside $22 | Overweight Reiterated | 27 Feb 2025 |
Financial journalist opinion
Based on 7 articles about ARDT published over the past 30 days









